GO
Loading...

Medicine

More

  • AbbVie will spend about $21 billion to buy fellow drugmaker Pharmacyclics in a bid to add another major revenue producer to a product portfolio that already includes the world's top-selling drug, the anti-inflammatory Humira. AbbVie executives told analysts Thursday morning that their company could reap more than $7 million in annual sales from...

  • AbbVie will pay $261.25 per share in cash and stock, a 13 percent premium to Pharmacyclics stock's closing price on Wednesday on the Nasdaq. Pharmacyclics stockholders can elect cash, AbbVie stock or a combination, subject to proration, the company said in a statement. "Imbruvica is not only complementary to AbbVie's oncology pipeline, it has demonstrated...

  • LOS ANGELES— Four patients at Cedars-Sinai Medical Center have been infected with an antibiotic-resistant "superbug" linked to a type of medical scope that's used on more than a half-million people in the U.S. every year, the hospital said Wednesday. Cedars said in a statement that it halted such procedures after learning about the UCLA outbreak and launched...

  • FDA approves Bristol-Myers drug for lung cancer Wednesday, 4 Mar 2015 | 2:22 PM ET

    WASHINGTON— The Food and Drug Administration on Wednesday expanded approval of an innovative Bristol-Myers Squibb drug to treat the most common form of lung cancer. The FDA first approved Bristol's drug in December for melanoma, the deadliest form of skin cancer. Evercore ISI analyst Mark Schoenebaum said in an investment note that Opdivo could garner sales...

  • What is Dengue fever?  Wednesday, 4 Mar 2015 | 11:13 AM ET

    Here are five things you need to know about Dengue fever.

  • LONDON, March 4- The idea of using vaccines to fight cancer has received a shot in the arm from a $1 billion deal between Bristol-Myers Squibb and Bavarian Nordic. Unfortunately, they have run into problems in practice, leading to a series of failures with experimental products such as Merck KGaA's Stimuvax and GlaxoSmithKline's MAGE-A3. The idea of combining...

  • COPENHAGEN, March 4- Bavarian Nordic has struck a prostate cancer drug deal with Bristol-Myers Squibb that could be worth $1 billion should its trials, part of a new field in cancer treatment, be successful. The jump added over $260 million to its market value of $880 million. In that trial, patients were treated with Prostvac in addition to escalating doses of...

  • The number of men being prescribed testosterone jumped more than 75 percent, to 2.3 million, between 2009 and 2013. About 70 percent of these patients were between the ages of 40 and 64, the FDA said. AbbVie Inc's AndroGel, one of the most widely-used products, raked in sales of $934 million in 2014. Other products include Endo International Plc's Testim and Eli...

  • FDA warning: men's testosterone drugs overused Tuesday, 3 Mar 2015 | 12:10 PM ET

    Additionally, the FDA cautioned that the drugs may increase the risk of heart attack, stroke and other cardiovascular problems. Drugmakers must add information about that potential risk to their prescribing labels and conduct a long-term study to further examine the issue, the FDA said. The FDA action follows years of industry marketing for new gels, patches...

  • NEW YORK— Pfizer's blockbuster vaccine against pneumonia and other bacterial infections has won another approval, for use in European Union residents aged 18 and older. New York- based Pfizer says more than 750 million doses have been distributed worldwide. Last year, Prevnar's global sales reached $4.5 billion, making it the No. 2 product for the company, which...

  • CONAKRY, March 3- Guinea's economy is likely to take a $2 billion hit from a regional Ebola outbreak that has killed nearly 10,000 people, and the country is relying on mining to drive growth once the virus is contained, the finance minister said. Guinea is the world's top exporter of the aluminium ore bauxite and produces diamonds and gold but its economy,...

  • North Korea lifts Ebola travel restrictions Tuesday, 3 Mar 2015 | 7:09 AM ET

    TOKYO— North Korea has lifted severe restrictions on foreign travel it imposed last year to keep the Ebola virus from crossing its borders. One tour company that takes tourists into North Korea, Uri Tours, said on its website Tuesday that it had been told by the country's national airline that the ban had been lifted. North Korea's decision to set the restrictions...

  • Sirleaf told fellow regional leaders and delegates at an international conference on Ebola in Brussels that restoring economic growth in Liberia, Guinea and Sierra Leone is a long-term and costly task. She said that "the most important long-term response to Ebola rests on plans and strategies for economic recovery," adding that "this will require significant...

  • Biotech drugmaker Amgen Inc.' s blood cancer drug Kyprolis doubled the time it kept the disease from worsening, compared with rival drug Velcade, according to the company. Amgen, based in Thousand Oaks, California, on Sunday released interim results from its study. The Amgen- funded study, known by the acronym ENDEAVOR, included 929 patients who had relapsed after...

  • Cancer drug shows promise  Monday, 2 Mar 2015 | 1:17 PM ET

    Amgen's cancer drug Kyprolis demonstrated positive results in a study against Takeda's Velcade. Dr. Sean Harper, Amgen, discusses the benefit risk equation for both drugs.

  • NEW YORK— Medical device maker Boston Scientific said Monday it will pay $1.6 billion to buy the men's health and prostate health business of Endo International. Boston Scientific said it is gaining treatments for enlarged prostate, urinary incontinence caused by stress, and erectile dysfunction, and said the business has about $130 million in adjusted...

  • Nurse who survived Ebola sues Dallas hospital system Monday, 2 Mar 2015 | 12:14 PM ET

    DALLAS— The Dallas hospital that treated the first patient to be diagnosed in the U.S. with Ebola lied to Congress when it said its staff was trained to handle the deadly virus, a nurse who contracted the disease contends in a lawsuit filed Monday. Nina Pham, who was an intensive care unit nurse at Texas Health Presbyterian Hospital Dallas, says after being told last...

  • Under the proposed settlement, Basic Research will pay a refund of $25 per box after being sued by law firms on behalf of consumers who purchased the product called Akavar beginning in 2007.. A Basic Research representative didn't respond to requests for comment. In 2007, a proposed class-action lawsuit was filed in U.S. District Court in Utah against Basic...

  • U.S., Liberia kick off trial of Ebola drug ZMapp Friday, 27 Feb 2015 | 12:50 PM ET

    CHICAGO, Feb 27- U.S. and Liberian researchers have started a clinical trial to test the safety and effectiveness of Mapp Biopharmaceutical Inc's Ebola drug ZMapp, an experimental treatment that has already been tried in a handful of Ebola patients, including two U.S. missionaries. The trial, a joint effort by the Liberian government and the National Institute...

  • Adults, as well as children of any age, will be enrolled in the study if they are admitted to Ebola treatment units in Liberia or are health care workers returning to the U.S. for treatment after being infected while serving in West Africa. That has happened to only two people— the nurses who treated patient Thomas Eric Duncan, who had traveled from Africa and died at a...